Benzimidazole analogues and related methods
The invention relates to compounds of the formula (VIII) wherein the moieties R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in the specification, and salts thereof, as well as their use, methods of use for them, methods of their synthesis, and the like. The compounds are protein tyrosine kinase inhibitors and can be used in the treatment of various cancer diseases and cancer-associated pain.
1. A compound of the Formula VIII
wherein:
R 1 is unsubstituted aryl or heteroaryl; or aryl or heteroaryl substituted one with one or two R 6 substituents;
R 2 is selected from the group consisting of H, (C 1 -C 3 )alkyl, halo, —CN, —O—(C 1 -C 3 )alkyl, —O—(CH 2 ) n X, —N(R 7 )(R 8 ), —CONH(CH 2 ) n X, —SO 2 NH(CH 2 ) n X, and —SO 2 (C 1 -C 3 )alkyl;
R 3 and R 4 are each independently H, (C 1 -C 6 )alkyl, or CN;
R 5 is —(C 1 -C 4 ) unsubstituted alkyl or (C 1 -C 3 ) alkyl substituted with one to three fluorines;
R 6 independently represents one or two of H, OH, NH 2 , (C 1 -C 3 )alkyl, halo, —CN, —O(C 1 -C 3 )alkyl, —O(CH 2 )nX, —N(R 7 )(R 8 ), —CONH 2 , —CONH(CH 2 ) n X, —SO 2 NH(CH 2 ) n X, or —SO 2 (C 1 -C 3 )alkyl; X is OR 9 or N(R 7 )(R 8 );
R 7 and R 8 are each independently hydrogen or (C 1 -C 4 )alkyl or (C 1 -C 4 )alkoxy, or R 7 and R 8 together form a ring; n is 2 or 3; and
R 9 is H or (C 1 -C 3 )alkyl; and salts, stereoisomers, enantiomers, racemates, solvates, hydrates, polymorphs, and prodrugs thereof.
2. A compound of claim 1 , wherein the compound is selected from the group consisting of: N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide (Pz-1); 2-(4-(5-(1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)phenyl)-N-(5-(tert-butyl)isoxazol-3-yl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(2,3-dimethylphenyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(2-fluoropyridin-3-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(2,4-dimethoxyphenyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(thiophen-3-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(2,4-difluorophenyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(2,4-dichlorophenyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(2-methoxyphenyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(6-fluoropyridin-3-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(2-methoxypyridin-3-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(6-morpholinopyridin-3-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(4-(methylsulfonyflphenyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(pyrimidin-5-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-(6-methylpyridin-2-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide; and N-(5-(tert-butyl)isoxazol-3-yl)-2-(4-(5-phenyl-1H-benzo[d]imidazol-1-yl)phenyl)acetamide.
3. A pharmaceutical composition comprising: a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, diluent, or excipient.
4. The pharmaceutical composition of claim 3 , wherein the compound is N (5 (tert-butyl)isoxazol-3-yl)-2-(4-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)phenyl)acetamide (Pz-1), or a pharmaceutically acceptable salt thereof.
5. A method of treating a subject with a RET, TRK (A,B,C) and/or VEGFR2 dependent cancer, the method comprising administering an effective dose of the pharmaceutical composition of claim 3 to a subject in need thereof.
6. The method of claim 5 , wherein the pharmaceutical composition is administered in combination with any other anti-cancer agent.
7. The method of claim 5 , wherein the RET, TRK (A,B,C,) and/or VEGFR2 dependent cancer is selected from thyroid cancer, lung cancer, or breast cancer.
8. A method of inhibiting phosphorylation of RET comprising treating RET, TRK (A,B,C,) and/or VEGFR2 dependent cancer cells expressing the RET gene with an effective amount of a compound of claim 1 .
9. A method of inhibiting phosphorylation of VEGFR2/KDR comprising treating RET, TRK (A,B,C,) and/or VEGFR2 dependent cancer cells expressing the VEGFR protein with an effective amount of a compound of claim 1 .
10. A method of inhibiting proliferation of thyroid RET TRK (A,B,C,) and/or VEGFR1 dependent cancer cells comprising treating thyroid RET, TRK (A,B,C,) and/or VEGFR2 dependent cancer cells with an effective amount of a compound of claim 1 .
11. The method of claim 10 , wherein the thyroid cancer cells comprise MTC.
12. A method of inhibiting the activity of a tyrosine kinase, comprising treating RET, TRK (A,B,C,) and/or VEGFR2 dependent cancer cells with an effective amount of a compound of claim 1 .
13. The method of claim 12 , wherein the tyrosine kinase is selected from the group consisting of RET, Trk-A, Trk-B, Trk-C, FLT3-ITD, c-Kit, VEGFR, and PDGFR.
14. The method of claim 12 , wherein the compound exhibits inhibitory activity of the kinase domain with an IC 50 value<1 μM.
15. A method of treating RET, TRK (A,B,C,) and/or VEGFR2 dependent cancer-associated pain, comprising administering an effective amount of a pharmaceutical composition of claim 3 to a patient in need thereof.
16. A kit for the preparation of a pharmaceutical composition comprising:
a first container comprising a compound of claim 1 ; and
a second container comprising a pharmaceutically acceptable carrier, diluent, or excipient.